for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quest Diagnostics Inc

DGX.N

Latest Trade

125.21USD

Change

0.70(+0.56%)

Volume

285,808

Today's Range

123.71

 - 

126.08

52 Week Range

73.03

 - 

131.60

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
124.51
Open
124.25
Volume
285,808
3M AVG Volume
30.36
Today's High
126.08
Today's Low
123.71
52 Week High
131.60
52 Week Low
73.03
Shares Out (MIL)
134.30
Market Cap (MIL)
16,722.02
Forward P/E
15.21
Dividend (Yield %)
1.80

Next Event

Q3 2020 Quest Diagnostics Inc Earnings Release

Latest Developments

More

Quest Diagnostics Surpasses 10 mln COVID-19 Molecular Diagnostic Test Results Delivered To Date

FDA Authorizes New Quest Diagnostics Lab Method Designed To Increase Covid-19 Molecular Diagnostics Capacity

Quest Diagnostics Says During Past Week Surpassed 9.2 Mln Covid-19 Molecular Diagnostic Test Results Delivered To Date

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Industry

Healthcare Facilities

Contact Info

500 Plaza Dr

SECAUCUS, NJ

07094-3619

United States

+1.973.5202700

https://www.questdiagnostics.com/

Executive Leadership

Stephen H. Rusckowski

Chairman of the Board, President, Chief Executive Officer

Mark J. Guinan

Chief Financial Officer, Executive Vice President

James E. Davis

Executive Vice President, General Diagnostics

Michael E. Prevoznik

Senior Vice President, General Counsel

Catherine T. Doherty

Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing

Key Stats

2.11 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

7.7K

2018

7.5K

2019

7.7K

2020(E)

8.7K
EPS (USD)

2017

5.670

2018

6.310

2019

6.560

2020(E)

8.507
Price To Earnings (TTM)
22.63
Price To Sales (TTM)
2.22
Price To Book (MRQ)
2.86
Price To Cash Flow (TTM)
15.44
Total Debt To Equity (MRQ)
78.46
LT Debt To Equity (MRQ)
68.94
Return on Investment (TTM)
7.18
Return on Equity (TTM)
6.02

Latest News

Latest News

FACTBOX-Drugmakers rush to develop COVID-19 treatments

Drugmakers around the world are rushing to develop treatments for COVID-19, the fast-spreading respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Gilead Sciences Inc's remdesivir is at the forefront of the efforts to treat the disease...

Quest medical lab sees COVID-19 test speed at 'acceptable' level by September

Quest Diagnostics Inc <DGX.N> said on Thursday it expects to cut week-long turnaround times for COVID-19 tests by more than half to get to "acceptable" levels by September, responding to concerns that slow testing is hampering the U.S. response.

Quest expects COVID-19 tests turnaround time at 'acceptable' levels by Sept

Quest Diagnostics Inc said on Thursday it expects to get turnaround times for COVID-19 tests to "acceptable" levels by this September by boosting capacity and prioritizing the most at-risk patients.

Quest says many U.S. COVID-19 tests taking more than a week

Quest Diagnostics Inc said on Monday the turnaround for COVID-19 tests it is conducting in the United States has lengthened, with non-prioritized patients waiting a week or more on average for their results.

Quest sees Q2 revenue above estimates on demand for COVID-19 testing services

Quest Diagnostics reported preliminary second-quarter revenue above analysts' estimates on Monday, largely due to growing demand for its COVID-19 testing services.

BRIEF-Quest Diagnostics Says Turnaround Time For Tests Now 4-6 Days As Demand For COVID-19 Molecular Diagnostic Testing Continues To Surge

* QUEST DIAGNOSTICS SAYS DEMAND FOR COVID-19 MOLECULAR DIAGNOSTIC TESTING CONTINUES TO SURGE, CAUSING FURTHER DELAYS IN TURNAROUND TIMES

BRIEF-Humana To Offer Labcorp At-Home COVID-19 Test Collection, Collaborate With Walmart And Quest Diagnostics To Offer Drive-Thru Testing For Humana Members

* HUMANA TO OFFER LABCORP AT-HOME COVID-19 TEST COLLECTION AND COLLABORATE WITH WALMART AND QUEST DIAGNOSTICS TO OFFER DRIVE-THRU TESTING FOR HUMANA MEMBERS Source text for Eikon: Further company coverage:

BRIEF-Quest Diagnostics To Expand In Indiana With Acquisition Of Outreach Lab Businesses Of Community Health Network And Ascension St. Vincent

* QUEST DIAGNOSTICS TO EXPAND IN INDIANA WITH ACQUISITION OF OUTREACH LAB BUSINESSES OF COMMUNITY HEALTH NETWORK AND ASCENSION ST. VINCENT NOW SERVICED THROUGH MID AMERICA CLINICAL LABORATORIES

Quest Diagnostics sees faster-than-expected recovery in U.S. testing volumes

Quest Diagnostics said on Wednesday it saw a higher recovery in its testing volumes in the United States where state and local governments were slowly lifting restrictions after the coronavirus lockdowns.

BRIEF-Quest Diagnostics - Adj EPS For Q2 Of 2020 Could Be In Range Of Breakeven To Slightly Profitable

* QUEST DIAGNOSTICS INC - BELIEVES THAT ITS ADJUSTED EARNINGS PER SHARE FOR Q2 OF 2020 COULD BE IN RANGE OF BREAKEVEN TO SLIGHTLY PROFITABLE

BRIEF-Home State Health And Quest Diagnostics Team Up To Increase Access To Covid-19 Testing In Underserved Communities

* HOME STATE HEALTH AND QUEST DIAGNOSTICS TEAM UP TO INCREASE ACCESS TO COVID-19 TESTING IN UNDERSERVED COMMUNITIES Source text for Eikon: Further company coverage:

Quest Diagnostics' COVID-19 test kit gets FDA nod for emergency use

Quest Diagnostics said on Thursday it received emergency use authorization (EUA) for its self-collection COVID-19 test kit from the U.S. Food and Drug Administration, sending its shares up 3%.

Quest Diagnostics COVID-19 test kit gets FDA nod for emergency use

Quest Diagnostics on Thursday received emergency use authorization from the U.S. Food and Drug Administration for its self-collection COVID-19 test kit.

BRIEF-FDA Authorizes Quest Diagnostics Covid-19 Nasal Specimen Self-Collection Kit For Emergency Use

* FDA AUTHORIZES QUEST DIAGNOSTICS COVID-19 NASAL SPECIMEN SELF-COLLECTION KIT FOR EMERGENCY USE

Quest Diagnostics offers U.S. employers coronavirus testing as workers return

Quest Diagnostics Inc on Wednesday started offering blood tests, temperature monitoring and other tailored services to U.S. employers as they attempt to reopen factories and offices after months under coronavirus-led lockdowns.

BRIEF-Quest Diagnostics Says Scaling Up COVID-19 Lab Operations

* QUEST DIAGNOSTICS - LAUNCHED A NEW SUITE OF RETURN TO WORK SERVICES BUILT AROUND LARGE-SCALE WORKFORCE COVID-19 TESTING

Quest Diagnostics launches workforce testing for coronavirus

Quest Diagnostics Inc on Wednesday launched services to support large-scale testing for the new coronavirus, as companies look to bring employees back to offices safely. The company said it was scaling up its COVID-19 lab operations to accommodate expected demand. (Reporting...

BRIEF-Quest Diagnostics Says Board Declared Quarterly Cash Dividend Of $0.56 Per Share

* QUEST DIAGNOSTICS INC - BOARD DECLARED A QUARTERLY CASH DIVIDEND OF $0.56 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Quest Diagnostics Files Prelim Prospectus For Senior Notes Offering Size Not Disclosed - SEC Filing

* QUEST DIAGNOSTICS FILES PRELIM PROSPECTUS FOR SENIOR NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source : (https://bit.ly/2YQOa19) Further company coverage:

BRIEF-Ortho Clinical Diagnostics And Quest Diagnostics To Broaden Availability Of Covid-19 Antibody Testing

* ORTHO CLINICAL DIAGNOSTICS AND QUEST DIAGNOSTICS TO BROADEN AVAILABILITY OF COVID-19 ANTIBODY TESTING Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up